US 12,012,419 B2
Heterocyclic compound
Shinobu Sasaki, Kanagawa (JP); Yasutomi Asano, Kanagawa (JP); Hironobu Maezaki, Kanagawa (JP); and Ayumu Sato, Kanagawa (JP)
Assigned to Takeda Pharmaceutical Company Limited, Osaka (JP)
Appl. No. 17/280,634
Filed by Takeda Pharmaceutical Company Limited, Osaka (JP)
PCT Filed Sep. 27, 2019, PCT No. PCT/JP2019/038228
§ 371(c)(1), (2) Date Mar. 26, 2021,
PCT Pub. No. WO2020/067455, PCT Pub. Date Apr. 2, 2020.
Claims priority of application No. 2018-184966 (JP), filed on Sep. 28, 2018.
Prior Publication US 2021/0347786 A1, Nov. 11, 2021
Int. Cl. C07D 498/04 (2006.01); A61P 1/00 (2006.01)
CPC C07D 498/04 (2013.01) [A61P 1/00 (2018.01)] 15 Claims
 
1. A compound represented by the formula (I):

OG Complex Work Unit Chemistry
wherein
X is O or CH2;
Y is N or CR5;
R1 and R2are each independently a hydrogen atom or a halogen atom;
R3, R4 and R5 are each independently a hydrogen atom, a halogen atom, a hydroxy group, an optionally substituted C1-6 alkyl group, or an optionally substituted C1-6 alkoxy group;
one of R3and R4optionally forms, together with R5, an optionally substituted ring; and
ring A is an optionally further substituted ring, or a salt thereof.